Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Germline mutations in BRCA1 and BRCA2 are established breast and ovarian cancer susceptibility genes.
• Advances in gene sequencing have enabled detection of BRCA mutations in various cancers, both germline and somatic.
• Poly (ADP)-ribose polymerase inhibitors (PARPi) are approved for BRCA-mutated cancers, highlighting therapeutic implications.

Purpose of the Study:

• To review the clinical significance of DNA damage repair (DDR) gene mutations in gastrointestinal cancers.
• To focus on the specific role and implications of BRCA mutations within this context.
• To highlight emerging therapeutic targets within the DDR pathway.

Main Methods:

• Literature review of studies on DDR gene mutations in gastrointestinal cancers.
• Analysis of clinical data regarding the impact of BRCA mutations.
• Overview of ongoing clinical investigations for DDR pathway inhibitors.

Main Results:

• BRCA mutations are increasingly detected across various gastrointestinal cancers.
• BRCA mutations are associated with significant therapeutic implications, particularly with PARPi.
• Other DDR genes (ATM, ATR, CHK1) are emerging as potential therapeutic targets.

Conclusions:

• Mutations in DDR genes, especially BRCA, have growing clinical relevance in gastrointestinal cancers.
• Targeted therapies for DDR-mutated gastrointestinal cancers are expanding.
• Further research into DDR pathway inhibitors promises new treatment avenues for these cancers.